8E
8EG.F Euglena Co. Ltd
- Market cap
- EUR 243M
- P/E
- -
- P/B
- 1.30x
- ROE
- -1.4%
- Dividend yield
- 0.62%
- Fundamental score
- -
Ratios use the latest price and the current fiscal year annualized from 3 quarters up to Jun 2026.
Is 8EG.F undervalued?
Graham numberThe Graham number of Euglena Co. Ltd cannot be estimated reliably (it needs positive earnings and book value).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
Euglena Co. Ltd fundamental analysis
No fundamental analysis for Euglena Co. Ltd yet.
Euglena Co. Ltd stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About Euglena Co. Ltd
Euglena Co., Ltd. engages in the research, development, production, and sale of microalgae in Japan. It operates through there segments: Healthcare Business; Biofuel Business; and Other businesses. The company manufactures and sells health foods and cosmetics utilizing microalgae, such as euglena and chlorella. In addition, the company develops biofuel technology and environmental related technology for microalgae and industrial waste oil; development and research in agricul…
Full company profileEuglena Co. Ltd financial statements
2026 annualized: Fiscal year 2026 is not finished. Income statement and cash flow are annualized from 3 quarters up to Jun 30, 2026, the balance sheet is the latest quarter. Figures change when the annual report is published.
Euglena Co. Ltd annual financial statements (JPY; K = thousand, M = million, B = billion, T = trillion)
| Item | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 Anlz |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Income Statement | |||||||||||
| Revenue | 11.1B | 13.9B | 15.2B | 14.0B | 13.3B | 23.3B | 44.4B | 46.5B | 47.6B | 50.4B | 53.1B |
| Gross Profit | 8.14B | 10.2B | 11.0B | 9.96B | 9.49B | 15.0B | 31.0B | 31.8B | 33.3B | 35.0B | 36.7B |
| Operating Income | 694M | 951M | -1.38B | -7.46B | -1.81B | -3.96B | -3.46B | -1.47B | 301M | 3.12B | 3.17B |
| EBITDA | - | 1.67B | -337M | -8.64B | -706M | -2.44B | 1.31B | 1.34B | 3.77B | 5.70B | 2.86B |
| Net Income | 673M | 786M | -1.25B | -9.80B | -1.49B | -2.43B | -2.67B | -2.65B | -650M | -805M | -469M |
| EPS | - | 9.33 | -15 | -106 | -16 | -22 | -24 | -23 | -4.77 | -5.89 | -3.36 |
| Balance Sheet | |||||||||||
| Total Assets | 15.5B | 18.9B | 21.8B | 17.2B | 15.4B | 64.1B | 57.3B | 59.6B | 73.3B | 72.3B | 69.3B |
| Total Liabilities | 2.10B | 3.20B | 5.93B | 6.37B | 5.96B | 41.9B | 37.9B | 39.4B | 41.1B | 43.8B | 37.7B |
| Shareholders' Equity | 13.4B | 15.6B | 15.9B | 10.8B | 9.38B | 22.2B | 19.4B | 20.2B | 31.7B | 31.0B | 33.2B |
| Cash & Short-term Investments | 6.80B | 7.15B | 4.43B | 7.83B | 6.25B | 11.0B | 9.95B | 15.8B | 20.6B | 21.2B | 17.2B |
| Cash Flow | |||||||||||
| Operating Cash Flow | 914M | 153M | -1.24B | 1.09B | -1.22B | 1.50B | 924M | 365M | 2.65B | 5.19B | - |
| Capital Expenditure | 1.08B | 3.83B | 3.14B | 1.33B | 157M | 149M | 329M | 587M | 732M | 595M | 0.00 |
| Free Cash Flow | - | -3.70B | -4.50B | -289M | -1.61B | 1.17B | 428M | -222M | 1.91B | 4.59B | - |
| Ratios | |||||||||||
| ROE | 5.0% | 5.0% | -7.9% | -90.5% | -15.9% | -11.0% | -13.8% | -13.1% | -2.1% | -2.6% | -1.4% |
| ROA | 4.3% | 4.2% | -5.7% | -57.0% | -9.7% | -3.8% | -4.7% | -4.4% | -0.9% | -1.1% | -0.7% |
| Net Profit Margin | 6.1% | 5.7% | -8.3% | -70.2% | -11.2% | -10.4% | -6.0% | -5.7% | -1.4% | -1.6% | -0.9% |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
Euglena Co. Ltd dividends
- Dividend yield
- 0.62%
- Forward dividend
- 0.01 EUR
- Payout ratio
- -
- Ex-dividend date
- Dec 29, 2025
Last stock split: 5:1 on Sep 26, 2013.
Who owns Euglena Co. Ltd
- Insiders 18.72%
- Institutions 15.60%
- Public & others 65.68%
- Shares outstanding 140M
- Free float 116M
Euglena Co. Ltd company profile
- Company name
- Euglena Co. Ltd
- Ticker
- 8EG.F
- ISIN
- JP3944370000
- Exchange
- Frankfurt Exchange
- Sector
- Consumer Defensive
- Industry
- Personal Care Products
- Employees
- 793
- Fiscal year end
- September
- Address
- G-BASE Tamachi, Tokyo, Japan, 108-0014
- Phone
- 81 3 3453 4907
- Website
- euglena.jp
About Euglena Co. Ltd
Euglena Co., Ltd. engages in the research, development, production, and sale of microalgae in Japan. It operates through there segments: Healthcare Business; Biofuel Business; and Other businesses. The company manufactures and sells health foods and cosmetics utilizing microalgae, such as euglena and chlorella. In addition, the company develops biofuel technology and environmental related technology for microalgae and industrial waste oil; development and research in agriculture business comprising feed and fertilizer, bioinformatics, and social businesses; and invests in biotechnology related businesses. Further, the company provides genome analysis services. Euglena Co., Ltd. was incorporated in 2005 and is headquartered in Tokyo, Japan.
Euglena Co. Ltd management
10- Mr. Tomohiro WakaharaRepresentative Executive Officer, Co-CEO, CFiO & Director · born 1977
- Ms. Hiroko UemuraRep. Exe. Off., Co-CEO, Head of Human Res., Dom. Healthcare B2B Sales & New Buss. Dev. and Director · born 1978
- Mr. Mitsuru IzumoFounder, President & Representative Director · born 1980
- Dr. Kengo SuzukiExecutive Officer & CTO · born 1979
- Yuko SuzukiExecutive Officer of Legal Affairs
- Mr. Korehiro OdateExecutive Officer & Head of Energy Company
- Ms. Shoko TakahashiExecutive Officer & Bioinformatics Business Head · born 1988
- Mr. Yasuhiro FukutomiSpecial Officer & CSO
- Dr. Yukihiro Maru Ph.D.Professional Officer & CRO
- Yuichi HoshinoExecutive Officer & Head of Information Management